Michael N. Koss
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael N. Koss has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Anthony Gal
Department of Pathology, Emory School of Medicine, Atlanta, Georgia
2 shared publications- Ite A. Laird-Offringa
Department of Surgery, University of Southern California, Los Angeles, California
2 shared publications - Janice S Galler
Departments of Surgery and of Biochemistry and Molecular Biology, Norris Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90089-9176, USA
2 shared publications - Jeffrey A. Hagen
Division of Cardiothoracic Surgery, University of Southern California, 1510 San Pablo St, #514, Los Angeles, CA 90033, USA
2 shared publications - Kimberly D. Siegmund
Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, USA
2 shared publications - Peter W. Laird
Department of Epigenetics, Van Andel Institute, Grand Rapids, USA
2 shared publications
Latest Publications
- 1 September 2018
- Published by Elsevier in Seminars in Diagnostic Pathology
- Vol. 35 (5) , 324-333
Reprint of: The pathology of pulmonary sarcoidosis: update
- 1 September 2018
- Published by Elsevier in Seminars in Diagnostic Pathology
- Vol. 35 (5) , 324-333
Reprint of: The pathology of pulmonary sarcoidosis: update
- 18 June 2014
- Published by Springer Nature
- Vol. 1180, 323-336
Handling and Interpretation of the Medical Renal Biopsy
Renal biopsy is the gold standard for diagnosis of kidney disease; indeed, it allows for determination of the type, extent, site, and nature of renal involvement in medical diseases, and it alters the clinical diagnosis in as many as 25–50 % of cases. At the same time, it is a relatively safe procedure with life-threatening complications occurring in less than 0.1 % of biopsies. The diagnosis of renal biopsies is complex, requiring correlation of the findings in three modalities: light, immunofluorescence, and electron microscopy. For that reason, appropriate division and fixation of the renal biopsy is required, and protocols for these processes are provided.
- 18 June 2014
- Published by Springer Nature
- Vol. 1180, 323-336
Handling and Interpretation of the Medical Renal Biopsy
Renal biopsy is the gold standard for diagnosis of kidney disease; indeed, it allows for determination of the type, extent, site, and nature of renal involvement in medical diseases, and it alters the clinical diagnosis in as many as 25–50 % of cases. At the same time, it is a relatively safe procedure with life-threatening complications occurring in less than 0.1 % of biopsies. The diagnosis of renal biopsies is complex, requiring correlation of the findings in three modalities: light, immunofluorescence, and electron microscopy. For that reason, appropriate division and fixation of the renal biopsy is required, and protocols for these processes are provided.
- Open Access
- 10 July 2008
- Published by Springer Nature in Molecular Cancer
- Vol. 7 (1) , 62
Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer
Background: Lung cancer is the leading cause of cancer death in men and women in the United States and Western Europe. Over 160,000 Americans die of this disease every year. The five-year survival rate is 15% – significantly lower than that of other major cancers. Early detection is a key factor in increasing lung cancer patient survival. DNA hypermethylation is recognized as an important mechanism for tumor suppressor gene inactivation in cancer and could yield powerful biomarkers for early detection of lung cancer. Here we focused on developing DNA methylation markers for squamous cell carcinoma of the lung. Using the sensitive, high-throughput DNA methylation analysis technique MethyLight, we examined the methylation profile of 42 loci in a collection of 45 squamous cell lung cancer samples and adjacent non-tumor lung tissues from the same patients.Results: We identified 22 loci showing significantly higher DNA methylation levels in tumor tissue than adjacent non-tumor lung. Of these, eight showed highly significant hypermethylation in tumor tissue (p < 0.0001): GDNF, MTHFR, OPCML, TNFRSF25, TCF21, PAX8, PTPRN2 and PITX2. Used in combination on our specimen collection, this eight-locus panel showed 95.6% sensitivity and specificity.Conclusion: We have identified 22 DNA methylation markers for squamous cell lung cancer, several of which have not previously been reported to be methylated in any type of human cancer. The top eight markers show great promise as a sensitive and specific DNA methylation marker panel for squamous cell lung cancer.
- 10 July 2008
- Published by Springer Nature in Molecular Cancer
- Vol. 7 (1) , 62
Open AccessIdentification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer
Background: Lung cancer is the leading cause of cancer death in men and women in the United States and Western Europe. Over 160,000 Americans die of this disease every year. The five-year survival rate is 15% – significantly lower than that of other major cancers. Early detection is a key factor in increasing lung cancer patient survival. DNA hypermethylation is recognized as an important mechanism for tumor suppressor gene inactivation in cancer and could yield powerful biomarkers for early detection of lung cancer. Here we focused on developing DNA methylation markers for squamous cell carcinoma of the lung. Using the sensitive, high-throughput DNA methylation analysis technique MethyLight, we examined the methylation profile of 42 loci in a collection of 45 squamous cell lung cancer samples and adjacent non-tumor lung tissues from the same patients.Results: We identified 22 loci showing significantly higher DNA methylation levels in tumor tissue than adjacent non-tumor lung. Of these, eight showed highly significant hypermethylation in tumor tissue (p < 0.0001): GDNF, MTHFR, OPCML, TNFRSF25, TCF21, PAX8, PTPRN2 and PITX2. Used in combination on our specimen collection, this eight-locus panel showed 95.6% sensitivity and specificity.Conclusion: We have identified 22 DNA methylation markers for squamous cell lung cancer, several of which have not previously been reported to be methylated in any type of human cancer. The top eight markers show great promise as a sensitive and specific DNA methylation marker panel for squamous cell lung cancer.
- Open Access
- 29 October 2007
- Published by Springer Nature in Molecular Cancer
- Vol. 6 (1) , 70
Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma
Background: Lung cancer is the number one cancer killer of both men and women in the United States. Three quarters of lung cancer patients are diagnosed with regionally or distantly disseminated disease; their 5-year survival is only 15%. DNA hypermethylation at promoter CpG islands shows great promise as a cancer-specific marker that would complement visual lung cancer screening tools such as spiral CT, improving early detection. In lung cancer patients, such hypermethylation is detectable in a variety of samples ranging from tumor material to blood and sputum. To date the penetrance of DNA methylation at any single locus has been too low to provide great clinical sensitivity. We used the real-time PCR-based method MethyLight to examine DNA methylation quantitatively at twenty-eight loci in 51 primary human lung adenocarcinomas, 38 adjacent non-tumor lung samples, and 11 lung samples from non-lung cancer patients.Results: We identified thirteen loci showing significant differential DNA methylation levels between tumor and non-tumor lung; eight of these show highly significant hypermethylation in adenocarcinoma: CDH13, CDKN2A EX2, CDX2, HOXA1, OPCML, RASSF1, SFPR1, and TWIST1 (p-value << 0.0001). Using the current tissue collection and 5-fold cross validation, the four most significant loci (CDKN2A EX2, CDX2, HOXA1 and OPCML) individually distinguish lung adenocarcinoma from non-cancer lung with a sensitivity of 67–86% and specificity of 74–82%. DNA methylation of these loci did not differ significantly based on gender, race, age or tumor stage, indicating their wide applicability as potential lung adenocarcinoma markers. We applied random forests to determine a good classifier based on a subset of our loci and determined that combined use of the same four top markers allows identification of lung cancer tissue from non-lung cancer tissue with 94% sensitivity and 90% specificity.Conclusion: The identification of eight CpG island loci showing highly significant hypermethylation in lung adenocarcinoma provides strong candidates for evaluation in patient remote media such as plasma and sputum. The four most highly ranked loci, CDKN2A EX2, CDX2, HOXA1 and OPCML, which show significant DNA methylation even in stage IA tumor samples, merit further investigation as some of the most promising lung adenocarcinoma markers identified to date.
- 29 October 2007
- Published by Springer Nature in Molecular Cancer
- Vol. 6 (1) , 70
Open AccessIdentification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma
Background: Lung cancer is the number one cancer killer of both men and women in the United States. Three quarters of lung cancer patients are diagnosed with regionally or distantly disseminated disease; their 5-year survival is only 15%. DNA hypermethylation at promoter CpG islands shows great promise as a cancer-specific marker that would complement visual lung cancer screening tools such as spiral CT, improving early detection. In lung cancer patients, such hypermethylation is detectable in a variety of samples ranging from tumor material to blood and sputum. To date the penetrance of DNA methylation at any single locus has been too low to provide great clinical sensitivity. We used the real-time PCR-based method MethyLight to examine DNA methylation quantitatively at twenty-eight loci in 51 primary human lung adenocarcinomas, 38 adjacent non-tumor lung samples, and 11 lung samples from non-lung cancer patients.Results: We identified thirteen loci showing significant differential DNA methylation levels between tumor and non-tumor lung; eight of these show highly significant hypermethylation in adenocarcinoma: CDH13, CDKN2A EX2, CDX2, HOXA1, OPCML, RASSF1, SFPR1, and TWIST1 (p-value << 0.0001). Using the current tissue collection and 5-fold cross validation, the four most significant loci (CDKN2A EX2, CDX2, HOXA1 and OPCML) individually distinguish lung adenocarcinoma from non-cancer lung with a sensitivity of 67–86% and specificity of 74–82%. DNA methylation of these loci did not differ significantly based on gender, race, age or tumor stage, indicating their wide applicability as potential lung adenocarcinoma markers. We applied random forests to determine a good classifier based on a subset of our loci and determined that combined use of the same four top markers allows identification of lung cancer tissue from non-lung cancer tissue with 94% sensitivity and 90% specificity.Conclusion: The identification of eight CpG island loci showing highly significant hypermethylation in lung adenocarcinoma provides strong candidates for evaluation in patient remote media such as plasma and sputum. The four most highly ranked loci, CDKN2A EX2, CDX2, HOXA1 and OPCML, which show significant DNA methylation even in stage IA tumor samples, merit further investigation as some of the most promising lung adenocarcinoma markers identified to date.
- 1 August 2007
- Published by Elsevier in Seminars in Diagnostic Pathology
- Vol. 24 (3) , 150-161
The pathology of pulmonary sarcoidosis: update
- 1 August 2007
- Published by Elsevier in Seminars in Diagnostic Pathology
- Vol. 24 (3) , 150-161
The pathology of pulmonary sarcoidosis: update